CoChat

Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795).

Kurzrock, R., Patnaik, A., Rosenstein, L., Fu, S., Papadopoulos, K. P., Smith, D. A., Falchook, G. S., Chambers, G., Gauvin, J. L., Naing, A., Smith, L. S., Gonzalez, T., Tsimberidou, A. M., Mays, T. A., Cox, D. S., Hong, D. S., DeMarini, D. J., Le, N. T., Morris, S. R., Tolcher, A. W. · 2011 · Journal of Clinical Oncology
Cited by 28

The DOI matches its Crossref record.

Abstract

3085 Background: The RAS/RAF/MEK and PI3K/AKT pathways are activated in many human cancers. GSK212 is a potent and selective allosteric inhibitor of MEK1/2 and GSK795 is a potent ATP-competitive inhibitor of all three isoforms of AKT. The objectives of this study were to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of GSK212 dosed in combination with GSK795 in adults with advanced solid tumors. Methods: Both GSK212 and GSK795 are given orally, once daily. This is a three-part study: Part 1, dose escalation; Part 2, expansion in selected tumor types to evaluate recommended Phase II doses (RP2D); Part 3, PK/PD assessment using tumor biopsies or FDG-PET. Results: 23 patients (pts) received ≥1 dose of GSK212 and/or GSK795 with 7 remaining on study. Dose escalation has proceeded using a zone-based escalation procedure enabling evaluation of multiple combination doses in parallel cohorts: 0.5mg GSK212 + 25, 50 or 75mg GSK795, 1mg or 1.5mg GSK212 + 25mg GSK795, and 1mg GSK212 + 50mg GSK795. Dose escalation is continuing. The RP2D for single-agent GSK212 is 2mg and the MTD for single agent GSK795 is 75mg. Dose-limiting toxicities (DLTs) are ≥14 day interruption of study drug for Grade 2 AST and ALT elevation and Grade 3 chest pain in association with sustained ventricular tachycardia. All DLTs were reversible with drug interruption. The most common adverse events (≥10%) were nausea (26%; G3/4 0%), AST elevation (22%; G3/4 9%), fatigue (22%; G3/4 0%), rash (22%; G3/4 0%), decreased appetite (17%; G3/4 0%), hypokalemia (17%; G3/4 0%), anemia (13%; G3/4 0%), confusional state (13%; G3/4 0%), dry mouth (13%; G3/4 0%), peripheral edema (13%; G3/4 0%), and vomiting (13%; G3/4 0%). At the lowest dose level (0.5mg/25mg) concentrations of each drug were similar when each compound was dosed alone or in combination. 3 of 13 pts evaluable for response had tumor regressions of 8% (ovarian), 16% (endometrial) and 17% (ovarian) after 8 weeks on study. Conclusions: The combination of the MEK1/2 inhibitor GSK212 and the AKT inhibitor GSK795 was well tolerated with reversible, predictable toxicities and has preliminary signals of clinical activity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2011.29.15_suppl.3085

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 28

Metadata

Authors
Kurzrock, R., Patnaik, A., Rosenstein, L., Fu, S., Papadopoulos, K. P., Smith, D. A., Falchook, G. S., Chambers, G., Gauvin, J. L., Naing, A., Smith, L. S., Gonzalez, T., Tsimberidou, A. M., Mays, T. A., Cox, D. S., Hong, D. S., DeMarini, D. J., Le, N. T., Morris, S. R., & Tolcher, A. W.
Venue
Journal of Clinical Oncology
Published
2011-05-20
Volume
29
Issue
15_suppl
Pages
3085-3085
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2590335801
Cited by
28
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795). https://app.cochat.ai/papers/10.1200/jco.2011.29.15_suppl.3085
The paper
Kurzrock, R., Patnaik, A., Rosenstein, L., Fu, S., Papadopoulos, K. P., Smith, D. A., Falchook, G. S., Chambers, G., Gauvin, J. L., Naing, A., Smith, L. S., Gonzalez, T., Tsimberidou, A. M., Mays, T. A., Cox, D. S., Hong, D. S., DeMarini, D. J., Le, N. T., Morris, S. R., & Tolcher, A. W. (2011). Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.29.15_suppl.3085

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.